![Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology](https://bjcardio.co.uk/wp-content/uploads/2018/04/PIONEER-2-Figure-1.png)
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
![Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. | Semantic Scholar Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f0fe7e1c19806567b88a0e30ebaf8e058543036c/4-Table4-1.png)
Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. | Semantic Scholar
![Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire](https://mms.businesswire.com/media/20170827005045/en/608826/4/Efficacy_Combined_2.jpg)
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
![Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire](https://mms.businesswire.com/media/20170827005045/en/608823/5/PEP_110mg.jpg)
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
![Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | AETOSWire Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | AETOSWire](https://www.aetoswire.com/blog/pic04295.jpg)
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | AETOSWire
![RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology](https://challengesincardiology.com/wp-content/uploads/2017/09/Diapositivo8.png)
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
![Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients](https://onlinelibrary.wiley.com/cms/asset/a228acd8-329c-4a1e-9bf0-b0720ac65064/clc22572-fig-0002-m.jpg)
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients
![Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: The RE-DUAL PCI trial subanalysis Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: The RE-DUAL PCI trial subanalysis](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/pcr-publications/young-eapci-pcr-journal-club/switching-oral-anticoagulation-therapy-pci-atrial-fibrillation-re-dual-pci-trial-subanalysis/12257244-21-eng-GB/Switching-of-oral-anticoagulation-therapy-after-PCI-in-patients-with-atrial-fibrillation-The-RE-DUAL-PCI-trial-subanalysis.jpg)
Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: The RE-DUAL PCI trial subanalysis
![Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis. - Abstract - Europe PMC Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6045730/bin/openhrt-2018-000785f02.jpg)
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis. - Abstract - Europe PMC
![Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions](https://www.jacc.org/cms/asset/0f878952-5093-4326-8522-37e5b401b7c1/gr4.jpg)
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
![Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions](https://www.ahajournals.org/cms/asset/b33bff6c-21f0-4669-b290-c94137190289/circinterventions.119.008349.fig05.jpg)
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
![Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? - European Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? - European](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2118088519/2085755151/gr1.jpg)
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? - European
![RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology](https://challengesincardiology.com/wp-content/uploads/2017/09/Diapositivo3.png)